Catechol-O-Methyltransferase val158met Polymorphism Predicts Placebo Effect in Irritable Bowel Syndrome
Open Access
- 23 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e48135
Abstract
Identifying patients who are potential placebo responders has major implications for clinical practice and trial design. Catechol-O-methyltransferase (COMT), an important enzyme in dopamine catabolism plays a key role in processes associated with the placebo effect such as reward, pain, memory and learning. We hypothesized that the COMT functional val158met polymorphism, was a predictor of placebo effects and tested our hypothesis in a subset of 104 patients from a previously reported randomized controlled trial in irritable bowel syndrome (IBS). The three treatment arms from this study were: no-treatment (“waitlist”), placebo treatment alone (“limited”) and, placebo treatment “augmented” with a supportive patient-health care provider interaction. The primary outcome measure was change from baseline in IBS-Symptom Severity Scale (IBS-SSS) after three weeks of treatment. In a regression model, the number of methionine alleles in COMT val158met was linearly related to placebo response as measured by changes in IBS-SSS (p = .035). The strongest placebo response occurred in met/met homozygotes treated in the augmented placebo arm. A smaller met/met associated effect was observed with limited placebo treatment and there was no effect in the waitlist control. These data support our hypothesis that the COMT val158met polymorphism is a potential biomarker of placebo response.Keywords
This publication has 55 references indexed in Scilit:
- COMT Val158Met Genotype Determines the Direction of Cognitive Effects Produced by Catechol-O-Methyltransferase InhibitionBiological Psychiatry, 2012
- Active Albuterol or Placebo, Sham Acupuncture, or No Intervention in AsthmaNew England Journal of Medicine, 2011
- Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot studyPharmacogenetics and Genomics, 2010
- Biological, clinical, and ethical advances of placebo effectsThe Lancet, 2010
- Which patients improve: Characteristics increasing sensitivity to a supportive patient–practitioner relationshipSocial Science & Medicine, 2010
- Patient and Practitioner Influences on the Placebo Effect in Irritable Bowel SyndromePsychosomatic Medicine, 2009
- Neurobiological Mechanisms of Placebo ResponsesAnnals of the New York Academy of Sciences, 2009
- Components of placebo effect: randomised controlled trial in patients with irritable bowel syndromeBMJ, 2008
- Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'BMC Bioinformatics, 2007
- Consequences of Variations in Genes that affect Dopamine in Prefrontal CortexCerebral Cortex, 2007